The Latest Cardiac and Vascular News
Quebec City, Quebec, April 26, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received Health Canada approval for the SavvyWire™, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR. […]
For the first time, heart failure patients can have full visibility of their hearts’ LA pressure and self-adjust their medication to stop further deterioration and avoid hospitalizations April 26, 2022 08:30 AM Eastern Daylight Time TEL AVIV, Israel–(BUSINESS WIRE)–Vectorious Medical Technologies Ltd., today announced that it has enrolled the first […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). ARO-ANG3 is the company’s investigational RNA interference (RNAi) therapeutic designed to silence the hepatic […]
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Franklin Mountain Medical announced today that the company has received FDA clearance of its patented UltraNav Transseptal Catheter System for controlled access and delivery of cardiovascular catheters and guidewires to the heart chambers via transseptal puncture. The success of transseptal procedures depends on the clinician’s ability to adequately […]
SedLine Was Also Associated with Reduction in Bleeding During Surgery and Shorter Duration on Mechanical Ventilation IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Cardiothoracic and Vascular Anesthesia in which Dr. André Denault and colleagues at the Montreal Heart Institute and Centre Hospitalier […]
– The CLEAR ACS trial is designed to evaluate the efficacy of NEXLIZET on short-term LDL-C lowering following those with a recent ACS event and at very high risk of recurrent CV event in a diverse patient population that is often underrepresented in clinical trials – ANN ARBOR, Mich., […]
April 20, 2022 New research proposes a four-stage system for measuring the progression of cardiovascular disease (CAD) based on atherosclerotic plaque – not secondary symptoms of heart disease. Quantification of CAD burden and plaque type has demonstrated to be the strongest discriminant of future risk of Major Adverse Cardiac Events […]
Istaroxime significantly improved the systolic blood pressure profile WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced positive primary results with istaroxime in rapidly raising systolic blood pressure, the […]
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company’s global growth journey NEW DELHI and HECHINGEN, Germany, April 19, 2022 /PRNewswire/ — Translumina, a global developer and manufacturer of innovative cardiovascular medical devices used in interventional cardiology, announces the launch of VIVO ISAR, its latest generation dual drug polymer-free coated stent (DDCS), in […]
JACKSONVILLE, Fla., April 18, 2022 /PRNewswire/ — The American Society for Preventive Cardiology (ASPC) announces the official program for the ASPC 2022 Congress on CVD Prevention, scheduled July 29-31, 2022 in Louisville, KY. The program covers the “ABCs of Preventive Cardiology” over the 2.5 day live, in-person program, and can be found on aspconline.org/2022congress. Included in the […]
